Zweig-DiMenna Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Zweig-DiMenna Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-83,500	Closed	-$4.71M	–	296
2015 Q3	$4.71M	Buy	+83,500	New	+$5.41M	0.2%	104
2015 Q2	–	Sell	-77,490	Closed	-$4.83M	–	316
2015 Q1	$4.83M	Buy	77,490 +4,000	+5%	+$233K	0.2%	110
2014 Q4	$4.23M	Buy	+73,490	New	+$4.09M	0.18%	120

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Zweig-DiMenna Associates's TEVA Position: Q4 2015 in Review

Zweig-DiMenna Associates sold out of Teva Pharmaceuticals (TEVA) in Q4 2015, closing a stake of 83,500 shares — an estimated $4.71M sold.

Zweig-DiMenna Associates first reported a position in TEVA in Q4 2014 and held it in 3 quarters. The position peaked at $4.83M in Q1 2015. 876 funds tracked by Wall St. Rank hold TEVA as of Q4 2015.

Zweig-DiMenna Associates reported no remaining Teva Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Zweig-DiMenna Associates sold 83,500 Teva Pharmaceuticals shares in Q4 2015, an estimated $4.71M.
Zweig-DiMenna Associates first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 3 quarters.
Zweig-DiMenna Associates's Teva Pharmaceuticals position peaked at $4.83M in Q1 2015.
876 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2015.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2015, filed 10 Feb 2016.